Urokinase, acting directly on the endogenous fibrinolytic system, can
catalyze the lysis of fibrinogen into fibrinolytic enzyme, which can not only
degrade fibrinogen clots, but also degrade fibrinogen, coagulation factor Ⅴ and
coagulation factor in blood circulation, so as to play the role of thrombolysis.
This product has a quick effect on the newly formed thrombus and good effect.
The product can also improve the activity of vascular ADP enzyme, inhibit
ADP-induced platelet aggregation and prevent thrombosis. After intravenous
infusion, the activity of fibrinolytic enzyme in patients was significantly
increased. A few hours after discontinuation of the drug, plasminase activity
returns to its original level, but the decrease in plasma fibrin or fibrinogen
levels, and the increase in their degradation products, lasts for 12 to 24
hours. Thrombolytic effect was significantly correlated with drug dose and time
window of administration.
The toxicity of the product was very low, and the 50%
lethal dose was more than 1 million IU/kg body weight in mice when given
intravenously. No obvious antigenicity, teratogenicity, carcinogenicity and
mutagenicity. There are few reports of allergic reaction in clinical
application. However, since this product increases plasminogen activity and
reduces unbound plasminogen and fibrin-bound plasminogen in circulation, there
may be a serious risk of bleeding.
Above is the relevant content summarized by Kang Yuan's editor. If you want
to know more, please follow us. We will update you regularly about Human
Chorionic Gonadotropin, Human Menopausal Gonadotropin supplier, Urofollitropin
price, Urokinase manufacturer, Hormone API manufacturer.